NewswireToday - /newswire/ -
Paris, Ile-de-France, France, 2010/02/03 - Pherecydes Pharma, BMSystems' spin-off, is becoming a US reference in the field of biosecurity and biodefense and a credible partner for protein, antibody & enzyme improvements. Publication and third invitation to present in the U.S.
Pherecydes Pharma, BMSystems' spin-off, is becoming a US reference in the field of biosecurity and biodefense and a credible partner for protein, antibody & enzyme improvements.
· Pherecydes-Pharma invited for the third* time to present at a biosecurity and biodefense conference in the US. Pherecydes Pharma, our funded & operational spin-off, is selected to present a poster at the 8th edition of the ASM Biodefense and Emerging Diseases Research Meeting in Baltimore (February 21-24, 2010), the company will introduce its latest innovations (3 patents) that provide a long-term sustainable answer to unknown multi-resistant bacterial threats.
· First paper accepted in a US reference Biodefense/biosecurity publication. We are proud to announce that a Pherecydes/BMSystems paper entitled "Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria" is accepted for publication in the June 2010 issue of Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science.
· Pherecydes-Pharma, a credible partner in the challenge of protein improvement. The TAPE technology is a new powerful method for creating high diversity in DNA sequences, while preserving intact internal domains for protein improvements such as antibodies, enzymes, etc... In biodefense, the company offers to use TAPE for addressing viral and toxin threats and is opened to industrial/academics collaborations.
· For more information, visit pherecydes-pharma.com/.
Pherecydes-Pharma was created in 2007 from an internal CADI** research program at Bio-Modeling Systems designed to provide a long-term sustainable answer to unknown multi-resistant bacterial threats. In less than three years Pherecydes-Pharma transformed a series of scientific breakthroughs into functional industrial methods for addressing infectious diseases and protein diversification.
January 20, 2010: Strategic Industrial biotech Partner News: ARD, leader of our "Synthons" collaborative Industrial Biotech program, announced the successful start-up and commissioning of the world’s first renewable succinic acid plant with an initial annual capacity of 2,000 metric tons.
For sustainable business, time to market is a critical issue. Why wait for the failure of your strategic internal R&D plan before starting your external Plan B?
Bio-Modeling Systems, a world leading R&D booster for life sciences discoveries, can help you save considerable time and resources immediately.
*2009: Houston USA: May 3-7 2009: 12th NSTI Nanotech conference. Innovative Phages Applications
*2008: Atlanta Georgia USA, June 23-25, 2008: Knowledge Foundation. 12th Biodetection Technologies conference
**CADI: Computer Assisted Deductive Integration.